kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human CDK5/p35NCK, active protein kinase,10 µg  

Recombinant human CDK5/p35NCK, active protein kinase,10 µg

Recombinant human Cyclin-dependent protein kinase 5 (CDK5) in active complex with p35NCK, active enzyme

Alternate names: CDK5, p35NCK, PSSALRE, cyclin-dependent kinase 5, Tau protein kinase II catalytic subunit, TPKII catalytic subunit/p35nck5a, CDK5 activator, NCK5A, p25

More details


Availability: on stock

475,00 €

Cdks are the catalytic subunits of serine/threonine protein kinases which are involved in the progression through the cell cycle. Despite its high degree of homology to other cyclin-dependent kinases, Cdk5 is not activated by cyclins and there is no indication for a role in cell cycle regulation. The formation of a functional holoenzyme results upon interaction with activators p35, p39, p25 and p29. Cdk5 is expressed in all tissues, but its highest expression and activity is present in postmitotic neurons. Activated CDK5 is involved in several processes including neuronal migration, neurotransmitter release, neuronal plasticity, memory, learning, addiction, and apoptosis. Aberrant Cdk5 activity induced by the conversion of p35 to p25 plays a role in the pathogenesis of neurodegenerative diseases.

Human cyclin-dependent protein kinase CDK5, coexpressed in complex with p35NCK.

Theoretical MW GST-CDK5: 62.8 kDa
Theoretical MW GST-p35NCK: 64.0 kDa
Expression system: Baculovirus infected Sf9 cells
Purification: One-step affinity purification using glutathione agarose
Storage buffer: 50 mM Tris-HCl, pH 8.0; 100 mM NaCl, 5 mM DTT, 4 mM reduced glutathione, 20% glycerol
Protein concentration: 0.240 mg/ml (Bradford method using BSA as standard protein)
Method for determination of Km value & specific activity: Filter binding assay MAFC membrane
Specific activity: 11,000 pmol/mg x min

Entrez Gene ID: 1020/8851 
UniProtKB:  Q00535/Q15078

Ordering information: shipped on dry ice

Product specific literature references:

Wei FY, Tomizawa K. (2007) Cyclin-dependent kinase 5 (Cdk5): a potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus." Mini Rev Med Chem. 7(10):1070-4.

Angelo M, Plattner F, Giese KP. (2006) Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory." J Neurochem. 99(2):353-70.

Pareek TK, Kulkarni AB. (2006) Cdk5: a new player in pain signaling." Cell Cycle. 5(6):585-8.